Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lunai Bioworks Inc (LNAI)

Lunai Bioworks Inc (LNAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Medical Breakthroughs: 5 AI Innovators Redefining What's Possible

Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER – Baystreet.ca News Commentary – The healthcare AI market reached $21.66 billion in 2025 and analysts now project growth to $110.61...

CBLL : 21.42 (+0.61%)
ONMD : 1.3300 (+3.10%)
VPT.VN : 0.120 (-4.00%)
LNAI : 0.9860 (-0.62%)
ABSI : 3.56 (+1.14%)
VPTDF : 0.0918 (+1.21%)
Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance

AI-powered drug discovery and biodefense company engages pharma on CNS programs amid rising deal activity

LNAI : 0.9860 (-0.62%)
Financial Pressure Turns Healthcare AI From Pilots Into Profits

Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER – Baystreet.ca News Commentary – Healthcare providers shortened buying cycles from eight months to under seven as financial pressures...

VPT.VN : 0.120 (-4.00%)
CCLD : 3.09 (-1.28%)
ABSI : 3.56 (+1.14%)
LNAI : 0.9860 (-0.62%)
CAI : 28.24 (+0.86%)
VPTDF : 0.0918 (+1.21%)
Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market

SACRAMENTO, Calif. , Dec. 9, 2025 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotechnology company developing precision therapeutics, today announced the identification of three...

LNAI : 0.9860 (-0.62%)
Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models

Following peer-reviewed publication and independent expert review of findings, the LOI advances Lunai's tumor-regressing immune-cell platform toward scalable therapies for aggressive cancers

LNAI : 0.9860 (-0.62%)
Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy

Lunai Bioworks Announces Publication of Second-Generation Allogeneic Dendritic Cell Therapy Platform in the journal "Vaccines".

LNAI : 0.9860 (-0.62%)

Barchart Exclusives

This Dividend Giant Yielding 4.5% Is Wall Street’s Top Telecom Pick for 2026
JPMorgan just released a list of its 47 top stock picks for 2026, but only one comes from the telecom industry, a stock that features an attractive yield and improving cash flow outlook. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar